SOPH

SEC source: 0001840706-26-000121 · wk-form4_1775678645.xml · nonDerivative · entry 2

Xu Zhenyu · CIK 0002006362 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 644,952

F1 · shares: Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on April 2 and 3, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted by the Reporting Person and do not represent discretionary trades.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.69 to $4.98, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001840706-26-000125 · wk-form4_1775678678.xml · nonDerivative · entry 2

Muken Ross · CIK 0002005463 · President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 698,097

F1 · shares: Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on April 2 and 3, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted by the Reporting Person and do not represent discretionary trades.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.77 to $4.98, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001840706-26-000126 · wk-form4_1775678693.xml · nonDerivative · entry 2

Van Well Daan · CIK 0002006414 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 353,669

F1 · shares: Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on April 2 and 3, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted by the Reporting Person and do not represent discretionary trades.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.77 to $4.945, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001840706-26-000123 · wk-form4_1775678666.xml · nonDerivative · entry 2

CARDOZA GEORGE · CIK 0001518734 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 292,861

F1 · shares: Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on April 2 and 3, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted by the Reporting Person and do not represent discretionary trades.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.70 to $5.01, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001840706-26-000120 · wk-form4_1775678638.xml · nonDerivative · entry 2

Verma Abhimanyu · CIK 0002114540 · Chief Technology Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 204,400

F1 · shares: Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on April 2 and 3, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted by the Reporting Person and do not represent discretionary trades.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.74 to $4.96, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001840706-26-000128 · wk-form4_1775678710.xml · nonDerivative · entry 1

Menu Philippe · CIK 0002014308 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 283,852

F1 · shares: Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on April 2 and 3, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted by the Reporting Person and do not represent discretionary trades.

F2 · balance_after: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.62 to $4.95, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001840706-26-000124 · wk-form4_1775678672.xml · nonDerivative · entry 1

Camblong Jurgi · CIK 0002007050 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,731,450

F1 · shares: Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on April 2 and 3, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted by the Reporting Person and do not represent discretionary trades.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.71 to $4.95, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001840706-26-000122 · wk-form4_1775678653.xml · nonDerivative · entry 1

Valente Manuela · CIK 0002009280 · Chief People Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 221,651

F1 · shares: Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on April 2 and 3, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted by the Reporting Person and do not represent discretionary trades.

SEC source: 0001840706-26-000121 · wk-form4_1775678645.xml · nonDerivative · entry 1

Xu Zhenyu · CIK 0002006362 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 647,352

F1 · shares: Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on April 2 and 3, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted by the Reporting Person and do not represent discretionary trades.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.67 to $4.95, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001840706-26-000125 · wk-form4_1775678678.xml · nonDerivative · entry 1

Muken Ross · CIK 0002005463 · President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 700,521

F1 · shares: Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on April 2 and 3, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted by the Reporting Person and do not represent discretionary trades.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.6150 to $4.95, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001840706-26-000126 · wk-form4_1775678693.xml · nonDerivative · entry 1

Van Well Daan · CIK 0002006414 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 356,069

F1 · shares: Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on April 2 and 3, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted by the Reporting Person and do not represent discretionary trades.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.685 to $4.95, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001840706-26-000123 · wk-form4_1775678666.xml · nonDerivative · entry 1

CARDOZA GEORGE · CIK 0001518734 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 295,274

F1 · shares: Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on April 2 and 3, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted by the Reporting Person and do not represent discretionary trades.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.66 to $4.95, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001840706-26-000127 · wk-form4_1775678699.xml · nonDerivative · entry 3

Puylaert Kevin · CIK 0002119354 · Chief Sales Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 148,230

F2 · shares: Represents shares sold by the Reporting Person in the open market to satisfy tax obligations in connection with the vesting of restricted stock units on April 3, 2026. The sales were effected as a "sell to cover" transaction and do not represent discretionary trades.

SEC source: 0001840706-26-000127 · wk-form4_1775678699.xml · nonDerivative · entry 2

Puylaert Kevin · CIK 0002119354 · Chief Sales Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 148,260

F1 · shares: Represents shares sold by the Reporting Person in the open market to satisfy tax obligations in connection with the vesting of restricted stock units on April 2, 2026. The sales were effected as a "sell to cover" transaction and do not represent discretionary trades.

SEC source: 0001840706-26-000127 · wk-form4_1775678699.xml · nonDerivative · entry 1

Puylaert Kevin · CIK 0002119354 · Chief Sales Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 148,306

F1 · shares: Represents shares sold by the Reporting Person in the open market to satisfy tax obligations in connection with the vesting of restricted stock units on April 2, 2026. The sales were effected as a "sell to cover" transaction and do not represent discretionary trades.

SEC source: 0001840706-26-000120 · wk-form4_1775678638.xml · nonDerivative · entry 1

Verma Abhimanyu · CIK 0002114540 · Chief Technology Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 205,430

F1 · shares: Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on April 2 and 3, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted by the Reporting Person and do not represent discretionary trades.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.71 to $4.95, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001840706-26-000090 · wk-form4_1775213964.xml · derivative · entry 2

Menu Philippe · CIK 0002014308 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 164,671

Underlying: Ordinary Shares · 164,671 shares

Expires 2036-04-02

F2 · derivative.exercise_date: The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027, and then in equal monthly installments through April 2, 2030.

SEC source: 0001840706-26-000090 · wk-form4_1775213964.xml · nonDerivative · entry 1

Menu Philippe · CIK 0002014308 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 112,936

F1 · shares: Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to the Reporting Person's continued service with the Issuer through each applicable vesting date. 25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments through April 2, 2030.

SEC source: 0001840706-26-000085 · wk-form4_1775213934.xml · derivative · entry 2

Valente Manuela · CIK 0002009280 · Chief People Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 104,790

Underlying: Ordinary Shares · 104,790 shares

Expires 2036-04-02

F2 · derivative.exercise_date: The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027, and then in equal monthly installments through April 2, 2030.

SEC source: 0001840706-26-000085 · wk-form4_1775213934.xml · nonDerivative · entry 1

Valente Manuela · CIK 0002009280 · Chief People Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 71,869

F1 · shares: Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to the Reporting Person's continued service with the Issuer through each applicable vesting date. 25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments through April 2, 2030.

SEC source: 0001840706-26-000088 · wk-form4_1775213952.xml · derivative · entry 2

Camblong Jurgi · CIK 0002007050 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 628,743

Underlying: Ordinary Shares · 628,743 shares

Expires 2036-04-02

F2 · derivative.exercise_date: The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027, and then in equal monthly installments through April 2, 2030.

SEC source: 0001840706-26-000088 · wk-form4_1775213952.xml · nonDerivative · entry 1

Camblong Jurgi · CIK 0002007050 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 431,211

F1 · shares: Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to the Reporting Person's continued service with the Issuer through each applicable vesting date. 25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments through April 2, 2030.

SEC source: 0001840706-26-000089 · wk-form4_1775213958.xml · derivative · entry 2

Xu Zhenyu · CIK 0002006362 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 164,671

Underlying: Ordinary Shares · 164,671 shares

Expires 2036-04-02

F2 · derivative.exercise_date: The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027, and then in equal monthly installments through April 2, 2030.

SEC source: 0001840706-26-000089 · wk-form4_1775213958.xml · nonDerivative · entry 1

Xu Zhenyu · CIK 0002006362 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 112,936

F1 · shares: Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to the Reporting Person's continued service with the Issuer through each applicable vesting date. 25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments through April 2, 2030.

SEC source: 0001840706-26-000084 · wk-form4_1775213927.xml · derivative · entry 2

Van Well Daan · CIK 0002006414 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 142,216

Underlying: Ordinary Shares · 142,216 shares

Expires 2036-04-02

F2 · derivative.exercise_date: The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027, and then in equal monthly installments through April 2, 2030.

SEC source: 0001840706-26-000084 · wk-form4_1775213927.xml · nonDerivative · entry 1

Van Well Daan · CIK 0002006414 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 97,536

F1 · shares: Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to the Reporting Person's continued service with the Issuer through each applicable vesting date. 25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments through April 2, 2030.

SEC source: 0001840706-26-000091 · wk-form4_1775213969.xml · derivative · entry 2

Muken Ross · CIK 0002005463 · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 628,743

Underlying: Ordinary Shares · 628,743 shares

Expires 2036-04-02

F2 · derivative.exercise_date: The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027, and then in equal monthly installments through April 2, 2030.

SEC source: 0001840706-26-000091 · wk-form4_1775213969.xml · nonDerivative · entry 1

Muken Ross · CIK 0002005463 · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 431,211

F1 · shares: Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to the Reporting Person's continued service with the Issuer through each applicable vesting date. 25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments through April 2, 2030.

SEC source: 0001840706-26-000086 · wk-form4_1775213940.xml · derivative · entry 2

CARDOZA GEORGE · CIK 0001518734 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 164,671

Underlying: Ordinary Shares · 164,671 shares

Expires 2036-04-02

F2 · derivative.exercise_date: The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027, and then in equal monthly installments through April 2, 2030.

SEC source: 0001840706-26-000086 · wk-form4_1775213940.xml · nonDerivative · entry 1

CARDOZA GEORGE · CIK 0001518734 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 112,936

F1 · shares: Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to the Reporting Person's continued service with the Issuer through each applicable vesting date. 25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments through April 2, 2030.

SEC source: 0001840706-26-000092 · wk-form4_1775213976.xml · derivative · entry 2

Verma Abhimanyu · CIK 0002114540 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 119,760

Underlying: Ordinary Shares · 119,760 shares

Expires 2036-04-02

F2 · derivative.exercise_date: The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027, and then in equal monthly installments through April 2, 2030.

SEC source: 0001840706-26-000092 · wk-form4_1775213976.xml · nonDerivative · entry 1

Verma Abhimanyu · CIK 0002114540 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,136

F1 · shares: Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to the Reporting Person's continued service with the Issuer through each applicable vesting date. 25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments through April 2, 2030.

SEC source: 0001840706-26-000087 · wk-form4_1775213946.xml · derivative · entry 2

Puylaert Kevin · CIK 0002119354 · Chief Sales Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,335

Underlying: Ordinary Shares · 82,335 shares

Expires 2036-04-02

F2 · derivative.exercise_date: The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027, and then in equal monthly installments through April 2, 2030.

SEC source: 0001840706-26-000087 · wk-form4_1775213946.xml · nonDerivative · entry 1

Puylaert Kevin · CIK 0002119354 · Chief Sales Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,468

F1 · shares: Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to the Reporting Person's continued service with the Issuer through each applicable vesting date. 25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments through April 2, 2030.

SEC source: 0001840706-26-000104 · wk-form4a_1775652410.xml · derivative · entry 2

Valente Manuela · CIK 0002009280 · Chief People Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 104,790

Underlying: Ordinary Shares · 104,790 shares

Expires 2036-04-02

F3 · derivative.exercise_date: The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027, and then in equal monthly installments through April 2, 2030.

SEC source: 0001840706-26-000104 · wk-form4a_1775652410.xml · nonDerivative · entry 1

Valente Manuela · CIK 0002009280 · Chief People Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 224,248

F1 · shares: Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to the Reporting Person's continued service with the Issuer. 25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments through April 2, 2030.

F2 · balance_after: This Form 4/A amends the Form 4 filed on April 3, 2026 to correct the amount reported in Column 5 (Amount of Securities Beneficially Owned Following Reported Transaction), which was previously reported as 71,869 ordinary shares due to an inadvertent error. The correct amount is 224,248 ordinary shares.

SEC source: 0001840706-26-000106 · wk-form4a_1775652424.xml · derivative · entry 2

Menu Philippe · CIK 0002014308 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 164,671

Underlying: Ordinary Shares · 164,671 shares

Expires 2036-04-02

F3 · derivative.exercise_date: The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027, and then in equal monthly installments through April 2, 2030.

SEC source: 0001840706-26-000106 · wk-form4a_1775652424.xml · nonDerivative · entry 1

Menu Philippe · CIK 0002014308 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 286,552

F1 · shares: Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to the Reporting Person's continued service with the Issuer. 25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments through April 2, 2030.

F2 · balance_after: This Form 4/A amends the Form 4 filed on April 3, 2026 to correct the amount reported in Column 5 (Amount of Securities Beneficially Owned Following Reported Transaction), which was previously reported as 112,936 ordinary shares due to an inadvertent error. The correct amount is 286,552 ordinary shares.

SEC source: 0001840706-26-000107 · wk-form4a_1775652430.xml · derivative · entry 2

Camblong Jurgi · CIK 0002007050 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 628,743

Underlying: Ordinary Shares · 628,743 shares

Expires 2036-04-02

F3 · derivative.exercise_date: The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027, and then in equal monthly installments through April 2, 2030.

SEC source: 0001840706-26-000107 · wk-form4a_1775652430.xml · nonDerivative · entry 1

Camblong Jurgi · CIK 0002007050 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,734,050

F1 · shares: Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to the Reporting Person's continued service with the Issuer. 25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments through April 2, 2030.

F2 · balance_after: This Form 4/A amends the Form 4 filed on April 3, 2026 to correct the amount reported in Column 5 (Amount of Securities Beneficially Owned Following Reported Transaction), which was previously reported as 431,211 ordinary shares due to an inadvertent error. The correct amount is 3,734,050 ordinary shares.

SEC source: 0001840706-26-000103 · wk-form4a_1775652404.xml · derivative · entry 2

Xu Zhenyu · CIK 0002006362 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 164,671

Underlying: Ordinary Shares · 164,671 shares

Expires 2036-04-02

F3 · derivative.exercise_date: The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027, and then in equal monthly installments through April 2, 2030.

SEC source: 0001840706-26-000103 · wk-form4a_1775652404.xml · nonDerivative · entry 1

Xu Zhenyu · CIK 0002006362 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 650,052

F1 · shares: Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to the Reporting Person's continued service with the Issuer. 25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments through April 2, 2030.

F2 · balance_after: This Form 4/A amends the Form 4 filed on April 3, 2026 to correct the amount reported in Column 5 (Amount of Securities Beneficially Owned Following Reported Transaction), which was previously reported as 112,936 ordinary shares due to an inadvertent error. The correct amount is 650,052 ordinary shares.

SEC source: 0001840706-26-000110 · wk-form4a_1775652449.xml · derivative · entry 2

Van Well Daan · CIK 0002006414 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 142,216

Underlying: Ordinary Shares · 142,216 shares

Expires 2036-04-02

F3 · derivative.exercise_date: The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027, and then in equal monthly installments through April 2, 2030.

SEC source: 0001840706-26-000110 · wk-form4a_1775652449.xml · nonDerivative · entry 1

Van Well Daan · CIK 0002006414 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 358,774

F1 · shares: Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to the Reporting Person's continued service with the Issuer. 25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments through April 2, 2030.

F2 · balance_after: This Form 4/A amends the Form 4 filed on April 3, 2026 to correct the amount reported in Column 5 (Amount of Securities Beneficially Owned Following Reported Transaction), which was previously reported as 97,536 ordinary shares due to an inadvertent error. The correct amount is 358,774 ordinary shares.

SEC source: 0001840706-26-000109 · wk-form4a_1775652443.xml · derivative · entry 2

Muken Ross · CIK 0002005463 · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 628,743

Underlying: Ordinary Shares · 628,743 shares

Expires 2036-04-02

F3 · derivative.exercise_date: The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027, and then in equal monthly installments through April 2, 2030.

SEC source: 0001840706-26-000109 · wk-form4a_1775652443.xml · nonDerivative · entry 1

Muken Ross · CIK 0002005463 · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 703,121

F1 · shares: Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to the Reporting Person's continued service with the Issuer. 25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments through April 2, 2030.

F2 · balance_after: This Form 4/A amends the Form 4 filed on April 3, 2026 to correct the amount reported in Column 5 (Amount of Securities Beneficially Owned Following Reported Transaction), which was previously reported as 431,211 ordinary shares due to an inadvertent error. The correct amount is 703,121 ordinary shares.

SEC source: 0001840706-26-000108 · wk-form4a_1775652436.xml · derivative · entry 2

CARDOZA GEORGE · CIK 0001518734 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 164,671

Underlying: Ordinary Shares · 164,671 shares

Expires 2036-04-02

F3 · derivative.exercise_date: The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027, and then in equal monthly installments through April 2, 2030.

SEC source: 0001840706-26-000108 · wk-form4a_1775652436.xml · nonDerivative · entry 1

CARDOZA GEORGE · CIK 0001518734 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 297,794

F1 · shares: Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to the Reporting Person's continued service with the Issuer. 25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments through April 2, 2030.

F2 · balance_after: This Form 4/A amends the Form 4 filed on April 3, 2026 to correct the amount reported in Column 5 (Amount of Securities Beneficially Owned Following Reported Transaction), which was previously reported as 112,936 ordinary shares due to an inadvertent error. The correct amount is 297,794 ordinary shares.

SEC source: 0001840706-26-000105 · wk-form4a_1775652418.xml · derivative · entry 2

Puylaert Kevin · CIK 0002119354 · Chief Sales Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,335

Underlying: Ordinary Shares · 82,335 shares

Expires 2036-04-02

F3 · derivative.exercise_date: The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027, and then in equal monthly installments through April 2, 2030.

SEC source: 0001840706-26-000105 · wk-form4a_1775652418.xml · nonDerivative · entry 1

Puylaert Kevin · CIK 0002119354 · Chief Sales Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 148,854

F1 · shares: Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to the Reporting Person's continued service with the Issuer. 25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments through April 2, 2030.

F2 · balance_after: This Form 4/A amends the Form 4 filed on April 3, 2026 to correct the amount reported in Column 5 (Amount of Securities Beneficially Owned Following Reported Transaction), which was previously reported as 56,468 ordinary shares due to an inadvertent error. The correct amount is 148,854 ordinary shares.